Department of Pediatrics, University of Messina, Messina, Italy.
Eur J Paediatr Neurol. 2012 Jan;16(1):90-4. doi: 10.1016/j.ejpn.2011.10.005. Epub 2011 Nov 18.
Spinal muscular atrophy with respiratory distress (SMARD 1) is a very rare autosomal recessive motor neuron disorder that affects infants and is characterized by diaphragmatic palsy, symmetrical distal muscular weakness, muscle atrophy, peripheral sensory neuropathy and autonomic nerve dysfunction. SMARD 1 is inherited as an autosomal recessive trait and the mutations have been identified in the gene encoding immunoglobulin μ-binding protein 2 (IGHMBP2), located on chromosome 11q13. It is considered a fatal form of infantile motoneuron disease and most of the patients dies within the first 13 months of life. We present a female child with genetically confirmed SMARD 1 displaying a mild phenotype and no severe signs of respiratory involvement, typically found in this form, up to 38 months despite a diaphragmatic palsy diagnosed at 6 months of age. Therefore, our clinical observation suggests that respiratory failure is not secondary, in any case, to the diaphragmatic palsy but other pathogenetic mechanisms might be involved.
呼吸窘迫型脊髓性肌萎缩症(SMARD1)是一种非常罕见的常染色体隐性运动神经元疾病,主要影响婴儿,其特征为膈肌麻痹、对称性远端肌肉无力、肌肉萎缩、周围感觉神经病和自主神经功能障碍。SMARD1 呈常染色体隐性遗传特征,其突变已在位于 11q13 的免疫球蛋白μ结合蛋白 2(IGHMBP2)基因中被鉴定。它被认为是婴儿运动神经元病的一种致命形式,大多数患者在生命的头 13 个月内死亡。我们介绍了一位女性患儿,其基因确诊为 SMARD1,表现出轻度表型,且没有严重的呼吸受累迹象,这在该疾病中较为典型,但直到 38 个月时仍未出现,尽管其在 6 个月大时被诊断为膈肌麻痹。因此,我们的临床观察表明,呼吸衰竭并非继发于膈肌麻痹,而是可能涉及其他发病机制。